Renee Tierney, NP
Acute Care · Richmond, VANPI 1144511957
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,725 of the $5,346 with a category attached, or 88.4%. 29 manufacturers reported payments, led by Edwards Lifesciences at 27.5% of the total. Reporting peaked in 2021 at $1,722 and has fallen 62.2% since, to $651 in 2025. Among acute care clinicians in VA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 163 payments — averaging $32.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$1K
- Medtronic$752
- Boston Scientific$560
- Novartis$303
- Abbott$277
- Amgen$253
- plus $2K from 23 others
What the payments were for
- Travel & lodging$62112%
- Food & beverage$4,72588%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 33 | $1,471 |
| Medtronic | 9 | $752 |
| Boston Scientific | 11 | $560 |
| Novartis | 16 | $303 |
| Abbott | 13 | $277 |
| Amgen | 8 | $253 |
| AstraZeneca | 4 | $244 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 15 | $238 |
| Impulse Dynamics (USA) Inc. | 6 | $159 |
| Shape Memory Medical Inc. | 1 | $135 |
| Endologix LLC | 2 | $120 |
| Johnson & Johnson | 7 | $111 |
| Pfizer | 6 | $102 |
| Boehringer Ingelheim | 5 | $97 |
| Novo Nordisk | 3 | $63 |
| Scpharmaceuticals Inc. | 2 | $54 |
| Atricure, Inc. | 2 | $47 |
| Medicomp Inc | 2 | $46 |
| Alnylam Pharmaceuticals Inc. | 3 | $45 |
| Sanofi-aventis U.S. LLC | 2 | $43 |
| Actelion Pharmaceuticals US, Inc. | 2 | $39 |
| E.r. Squibb & Sons, L.L.C. | 3 | $38 |
| Cardiva Medical, Inc. | 1 | $31 |
| Merck | 2 | $26 |
| Daiichi Sankyo Inc. | 1 | $22 |
| Irhythm Technologies, Inc. | 1 | $20 |
| Philips North America LLC | 1 | $18 |
| Bridgebio Pharma, Inc. | 1 | $16 |
| Abiomed | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,346 in reported general payments places this provider in the 90th percentile of 599 acute care providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 113 | $96,293 |
| EntrestoSacubitril/Valsartan | 68 | $71,493 |
| FarxigaDapagliflozin Propanediol | 52 | $54,632 |
| XareltoRivaroxaban | 19 | $17,562 |
| JardianceEmpagliflozin | 20 | $12,996 |
| Nebivolol Hcl | 35 | $2,403 |
| Metoprolol Succinate | 129 | $2,133 |
| Flecainide Acetate | 40 | $1,102 |
| Midodrine Hcl | 15 | $1,033 |
| Losartan Potassium | 123 | $1,000 |
| Ezetimibe | 23 | $791 |
| Bumetanide | 26 | $736 |
| Doxazosin Mesylate | 40 | $710 |
| Rosuvastatin Calcium | 23 | $603 |
| Carvedilol | 100 | $585 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $102 | $96,293113 claims |
| NovartisEntresto | $303 | $71,49368 claims |
| AstraZenecaFarxiga | $244 | $54,63252 claims |
| Johnson & JohnsonXarelto | $111 | $17,56219 claims |
| Boehringer IngelheimJardiance | $97 | $12,99620 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 599 acute care providers in Virginia.
Other acute care in Richmond
- Rachel DukeRichmond$751K
- Mica FerlisRichmond$20K
- Jonathan PenderRichmond$13K
- Erin PerlmutterRichmond$13K
- Emily GilbertRichmond$10K
- Linda HazelgrenRichmond$9K
- Stephanie HerndonRichmond$9K
- Christine RobinsonRichmond$8K
- Kelly McAdamsRichmond$7K
- Linda KashiwabaraRichmond$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.